TELA Bio, Inc. — Earnings
Most recent reported period: FY2025 (Q4) (filed for period ending 2025-12-31) · sourced from SEC EDGAR
Recent earnings · last 8 quarters
| Quarter end | Revenue | YoY | Net Income | YoY | Op. Margin |
|---|---|---|---|---|---|
| 2025-12-31 | $21M | ↑+18.2% | — | — | — |
| 2025-09-30 | $21M | ↑+9.1% | $-9M | ↑+17.1% | -36.5% |
| 2025-06-30 | $20M | ↑+25.5% | $-10M | ↑+21.2% | -45.0% |
| 2025-03-31 | $19M | ↑+11.5% | $-11M | ↓-99.0% | -56.5% |
| 2024-12-31 | $18M | ↑+3.8% | — | — | — |
| 2024-09-30 | $19M | ↑+25.9% | $-10M | ↑+5.3% | -49.4% |
| 2024-06-30 | $16M | ↑+11.0% | $-13M | ↓-16.8% | -71.9% |
| 2024-03-31 | $17M | ↑+39.4% | $-6M | ↑+52.9% | -29.1% |
Analyst consensus estimates (EPS / Revenue) and implied move from options will land in a follow-up wave. For now, YoY-vs-prior-year-quarter is the surprise proxy.
Last earnings · FY2025 (Q4)
Earnings surprise · last 8 quarters
YoY % change · proxy for analyst surprise until estimates landEPS history · last 10 fiscal years
diluted, GAAP, annualNote: EPS reflects WEIGHTED-AVERAGE diluted shares for each fiscal year. Pre-stock- split values can blow up the early bars if SEC's XBRL data isn't split-adjusted — flagged as a known limitation; cumulative split-adjustment is a follow-up.
Margin trends · 31 quarters
margin trajectory tells the operating-leverage storyGo deeper
TELA Sankey — flow of dollars
See how revenue waterfalls through every line item to net income for the latest reported quarter, with prior-period comparison.
Open SankeyTELA Key Metrics — EPS, ROE, ROIC
10 CFA-grade fundamental ratios — EPS, BVPS, ROE, ROA, ROIC, Debt/Equity, Current Ratio. Compare across years.
Open Key Metrics